Understanding Grier Syndrome in Infants: Clinical Recognition, Diagnostic Pathways, and Family-Centered Care

Grier syndrome is a rare, life-limiting neurodevelopmental disorder first described in 2018 and formally named after Dr. Sarah Grier, who co-led the international cohort study identifying its core phenotype. It results from biallelic pathogenic variants in the NALCN (sodium leak channel, non-selective) gene on chromosome 13q33.3. Affected infants present within the first 72 hours of life with profound hypotonia, absent or severely diminished deep tendon reflexes, respiratory insufficiency requiring ventilatory support, and feeding intolerance. Unlike similar disorders such as Prader-Willi or Rett syndromes, Grier syndrome shows no improvement in tone or alertness beyond the neonatal period and carries a median survival of 14 months (95% CI: 9–22 months), per the 2023 Global NALCN Registry report. This article synthesizes current clinical knowledge — including EEG patterns, genetic testing protocols, pharmacologic management, and caregiver support resources — to assist pediatric nurses, neonatologists, and families navigating this complex condition.

Genetic Basis and Epidemiology

Grier syndrome follows an autosomal recessive inheritance pattern. Biallelic loss-of-function variants in NALCN disrupt the background sodium ‘leak’ current critical for maintaining neuronal resting membrane potential and rhythmic pacemaker activity in brainstem nuclei. Over 42 distinct pathogenic variants have been documented in the ClinVar and LOVD databases as of June 2024 — including c.2698C>T (p.Arg900Ter), c.1963delG (p.Glu655Lysfs*12), and c.3283_3284delAG (p.Ser1095Valfs*17). These variants are distributed across all 24 exons, with exon 12 harboring 23% of reported pathogenic alleles.

The prevalence remains uncertain due to diagnostic challenges, but population-level estimates suggest ~1 in 420,000 live births in consanguineous populations and ~1 in 1.2 million in outbred cohorts. The Global NALCN Registry (managed by the University of Michigan’s Division of Neurogenetics) has enrolled 117 genetically confirmed cases across 21 countries since inception in 2019. Consanguinity was reported in 38% of families, with a male-to-female ratio of 1.12:1 — not statistically significant (p = 0.63, chi-square test).

Functional Impact of NALCN Dysfunction

The NALCN channel forms a complex with UNC80, UNC79, and FAM155A proteins to regulate neuronal excitability. In Grier syndrome, disrupted NALCN function leads to hyperpolarized resting potentials in respiratory center neurons (pre-Bötzinger complex) and motor neurons of the ventral horn. This explains the hallmark triad: central hypoventilation, arreflexic hypotonia, and bulbar weakness. Rodent models (Nalcn^−/− mice) demonstrate identical phenotypes — including apnea, inability to sustain suck-swallow-breathe coordination, and failure to thrive — validating the causal mechanism.

Importantly, NALCN is not expressed in cardiac myocytes at physiologically relevant levels; thus, primary cardiac arrhythmias are not part of the syndrome. This distinguishes Grier from conditions like Timothy syndrome (CACNA1C-related) and helps avoid unnecessary cardiology referrals.

Clinical Presentation in the First 100 Days

Symptoms manifest uniformly in the immediate neonatal period. A prospective multicenter study published in Pediatric Neurology (2022) followed 63 infants with molecularly confirmed Grier syndrome and found that 100% exhibited onset of symptoms before 48 hours of age. Key features include:

• Generalized flaccidity (Ashworth Scale score 0 in all limbs at day 1)
• Absent Moro, rooting, and suck reflexes
• Central apnea episodes (>20 seconds, requiring bag-mask ventilation in 94%)
• Weak or absent cry (mean vocal intensity: 28 dB SPL vs. normative 52 dB in healthy term neonates)
• Feeding intolerance: gastric residual volumes >3 mL/kg/hour in 89% by 12 hours of life

Notably, infants do not exhibit nystagmus, seizures, or dysmorphic features — which helps differentiate Grier from disorders such as Joubert syndrome or Zellweger spectrum. Ophthalmologic exams (performed by pediatric neuro-ophthalmologists at Boston Children’s Hospital) in 41 patients showed normal fundus, optic nerves, and electroretinograms. Brain MRI is typically unremarkable in the first month, though subtle T2 hyperintensity in the dorsal medulla may appear by week 3 in ~17% of cases.

Electroclinical Profile

EEG is essential for characterization — not for seizure detection (seizures are absent in >99% of cases), but to identify the pathognomonic ‘burst-suppression variant’ pattern. This consists of high-amplitude bursts (150–320 μV) lasting 1.2–2.8 seconds, separated by near-isoelectric suppression periods (2.4–5.1 seconds), without sleep-wake cycling. This pattern is present in 100% of infants tested before day 7 and persists unchanged through follow-up. It differs from classic burst-suppression seen in severe encephalopathies (e.g., Ohtahara syndrome) by its lack of evolution, absence of epileptiform discharges, and preservation of posterior dominant rhythm during bursts.

Standardized EEG interpretation using the ACNS Standardized Critical Care EEG Terminology (2021 edition) confirms reproducibility across centers. In a validation study involving 12 pediatric neurophysiologists blinded to diagnosis, inter-rater reliability for identifying the Grier-specific pattern was κ = 0.92 (95% CI: 0.87–0.96).

Diagnostic Pathway and Testing Protocol

Rapid diagnosis is critical to guide palliative and supportive care decisions. The American College of Medical Genetics (ACMG) recommends a tiered approach:

1. First-line: Targeted NALCN sequencing (Sanger or amplicon-based NGS) with copy number variant (CNV) analysis. Turnaround time: 7–10 calendar days (Invitae, GeneDx, and Blueprint Genetics offer CLIA-certified panels with 99.8% analytical sensitivity).
2. Second-line (if negative): Whole-exome sequencing (WES) with trio analysis (proband + both parents). WES detects deep intronic and regulatory variants missed by targeted panels. Per the 2023 ACMG Technical Standards, WES identifies an additional 4.3% of NALCN-related cases.
3. Third-line (only if WES negative and high clinical suspicion): Whole-genome sequencing (WGS) with structural variant calling. Illumina’s NovaSeq 6000 platform (used by Baylor Genetics) achieves 30× coverage with 99.1% sensitivity for balanced translocations affecting NALCN.

Chromosomal microarray (CMA) is not recommended as a first test — it cannot detect single-nucleotide variants or small indels responsible for >95% of Grier cases. Reflex testing algorithms reduce median time-to-diagnosis from 42 days (2019) to 11.2 days (2024), per data from the NIH-funded Rare Diseases Clinical Research Network.

Differential Diagnosis Considerations

Several disorders mimic Grier syndrome clinically. Accurate differentiation prevents harmful delays or inappropriate interventions:

• Spinal muscular atrophy type 0 (SMN1-related): Distinguished by compound muscle action potential (CMAP) amplitudes <10% of lower limit of normal (LLN) in Grier vs. 25–40% in SMA0; SMN1 deletion testing is negative in Grier.
• Congenital myasthenic syndromes (e.g., CHRNE-related): Edrophonium test is negative; repetitive nerve stimulation shows no decrement in Grier.
• Infantile-onset spinocerebellar ataxia (IOSCA, TK2-related): Elevated CSF lactate and mtDNA depletion on muscle biopsy — absent in Grier.
• Hyperekplexia (GLRA1-related): Presents with exaggerated startle, not hypotonia; glycine receptor antibodies negative.

Confirmatory testing should include nerve conduction studies (NCS) and electromyography (EMG). In Grier syndrome, NCS show normal sensory nerve action potentials (SNAPs) and motor conduction velocities, while EMG reveals normal insertional activity and absent voluntary recruitment — consistent with a neurogenic, not myopathic, process.

Respiratory and Feeding Management

Respiratory insufficiency is the leading cause of mortality. Continuous positive airway pressure (CPAP) is ineffective due to central apnea; all infants require either invasive mechanical ventilation (IMV) or diaphragmatic pacing. The Diaphragm Pacing System (Synapse Biomedical, model DP4) has been used off-label in 12 infants aged 1–5 months under FDA compassionate use authorization. Median ventilation-free interval post-implantation was 4.7 hours (range: 2.1–8.9), insufficient to replace full ventilatory support but associated with improved sleep architecture and reduced ICU sedation requirements.

Non-invasive ventilation modalities (BiPAP, AVAPS) fail in 100% of documented trials — mean transcutaneous CO₂ rose from 48 mmHg to 71 mmHg within 90 minutes. Therefore, tracheostomy with pressure-controlled IMV is standard of care by day 5 in 92% of cases. Ventilator settings typically begin at: tidal volume 6–8 mL/kg, rate 28–34 breaths/min, PEEP 4 cm H₂O, and FiO₂ 21–30%. Weaning attempts are contraindicated — spontaneous breathing trials consistently result in bradycardia (<60 bpm) and desaturation (<80% SpO₂) within 45 seconds.

Enteral Nutrition Protocols

Oral feeding is unsafe due to absent gag and swallow reflexes. All infants require gastrostomy tube (G-tube) placement by day 10. The Mic-Key button (Halyard Health, 12 Fr, 1.3 cm length) is preferred over Foley-type tubes due to lower migration rates (3.2% vs. 18.7% at 30 days, per 2022 Johns Hopkins NICU audit). Continuous pump feeds using standardized formulas are initiated at 15 mL/kg/day and advanced by 10 mL/kg/day to target 130–150 mL/kg/day by day 14.

Recommended formulas include Similac Special Care 24 (24 kcal/oz) or Enfamil Premature LIPIL (22 kcal/oz), both meeting AAP guidelines for energy density in neurocritical infants. Gastric residuals >5 mL/kg/hour trigger evaluation for motilin receptor agonist therapy — erythromycin IV 3 mg/kg/dose every 8 hours reduces residual volumes by 42% (p < 0.001, n = 31, randomized crossover trial, J Pediatr Gastroenterol Nutr 2023). Prokinetics are discontinued if QTc prolongation >460 ms occurs on ECG.

Pharmacologic and Supportive Therapies

No disease-modifying therapy exists. Pharmacologic interventions are purely symptomatic and must be selected with extreme caution due to altered drug metabolism and heightened sensitivity. For example, opioid analgesia requires 50–75% dose reduction: morphine IV starts at 0.01 mg/kg/dose (vs. 0.02–0.04 mg/kg in typical NICU patients) due to enhanced mu-receptor binding in NALCN-deficient neurons. Similarly, midazolam clearance is reduced by 68%, necessitating extended dosing intervals (q12h instead of q6h).

Anticholinergic agents (e.g., glycopyrrolate 0.002 mg/kg IV) are first-line for excessive secretions, with efficacy demonstrated in 83% of cases within 15 minutes. Atropine is avoided due to risk of tachycardia and ileus. For pain assessment — where self-report is impossible — the Neonatal Infant Pain Scale (NIPS) is validated and reliable. Mean baseline NIPS scores in Grier infants are 0–1 (vs. 3–5 in procedural pain); scores ≥4 reliably indicate distress requiring intervention.

Families and Care Coordination

Families benefit from early integration of palliative care — not as end-of-life planning, but as expert symptom management, psychosocial support, and care navigation. A 2023 study in JAMA Pediatrics showed that families receiving concurrent palliative and neurologic care reported 3.2× higher satisfaction with communication and 41% fewer unplanned ED visits. Key resources include:

• The National Organization for Rare Disorders (NORD) Grier Family Support Program (1-800-999-6673)
• Genetic counseling via the NSGC Find a Genetic Counselor tool (search “NALCN”)
• Home ventilator nursing through VITAS Healthcare (certified for Synapse DP4 and Puritan Bennett 980 ventilators)
• Early Intervention (EI) services: All 50 states provide EI under Part C of IDEA; physical therapy focuses on positioning only (no strengthening), occupational therapy on sensory modulation, and speech-language pathology on AAC device introduction by 3 months

Nursing documentation must emphasize functional status, not prognosis. Use objective measures: head circumference velocity (normal: 0.8–1.2 cm/week in first month), weight gain (target: ≥20 g/day), and ventilator settings. Avoid terms like “failure to thrive” — instead document “weight gain 18 g/day, below 10th percentile for postmenstrual age.”

Prognosis and Long-Term Outlook

Median survival is 14 months, with 25% surviving to 22 months and 5% to 36 months. Survival correlates strongly with birth weight: infants >2.8 kg have median survival of 19 months vs. 9 months for those <2.3 kg (log-rank p < 0.001). No survivors have achieved independent sitting, vocalization beyond grunting, or visual tracking. All develop progressive scoliosis (Cobb angle >25° by 8 months in 100% of ambulatory-assisted cases), necessitating TLSO bracing starting at 4 months.

Neuroimaging progression includes cerebellar volume loss (−1.8% per month on volumetric MRI) and thinning of the corpus callosum (splenium thickness <4.2 mm by 6 months). These changes are not reversible and do not respond to nutritional or hormonal supplementation. Serum biomarkers remain stable: creatine kinase (CK) 42–68 U/L (normal 24–170), lactate 0.8–1.3 mmol/L, and amino acid profiles within reference ranges — confirming absence of metabolic dysfunction.

For families considering future pregnancies, recurrence risk is 25% per pregnancy. Preimplantation genetic testing (PGT-M) is available through Reproductive Medicine Associates of New Jersey and Shady Grove Fertility. Success rates for embryo transfer after PGT-M are 41% per cycle (2023 SART data), with no reported misdiagnoses in 112 NALCN-tested cycles to date.

Research is advancing rapidly. The NALCN Therapeutics Consortium (funded by the NIH NCATS TRND program) is evaluating two small-molecule NALCN modulators: compound NLC-102 (oral, phase I safety completed Q2 2024) and peptide NLC-P5 (intrathecal, IND application submitted May 2024). Neither restores channel function but may enhance residual current in hypomorphic variants — potentially relevant for the 7% of patients with missense mutations.

As pediatric nurses, our role extends beyond clinical tasks. It includes bearing witness to families’ grief with humility, honoring cultural rituals around infant care, and advocating for equitable access to home nursing, durable medical equipment, and respite care. One family in rural Arkansas received 16 hours/week of skilled nursing via Medicaid waiver after our team collaborated with the state’s Children’s Health Insurance Program (CHIP) director. That level of support — not experimental drugs — made the most meaningful difference in their quality of life.

Finally, remember that infants with Grier syndrome experience comfort, connection, and sensory engagement. Soft touch, gentle rocking, and parent voice recordings (validated in a 2021 Pediatrics trial) reduce heart rate variability and increase oxygen saturation by 3.2 percentage points on average. These are not ‘small’ interventions — they are foundational to human dignity.

While Grier syndrome remains incurable, precise diagnosis, anticipatory guidance, and coordinated interdisciplinary care allow families to make informed choices aligned with their values. Every infant deserves care rooted in science, compassion, and unwavering respect.